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CHLOROQUINE AS ANTINEOPLASTIC THERAPY
Preface
This is a collaborative Honors Program Project, co-authored by Alexandra Elise Mason
and Catherine Elaine Herron. We have chosen to submit the project in the Type III format, in
which both students independently submit the co-authored document including a preface
delineating their contributions to the project. This submission is that of Catherine Elaine Herron,
and this preface will detail the origin of our project as well as my personal contributions to the
work.
The idea for this project originated when Grace Lawrence, a Ph. D. nursing candidate
from George Mason University (GMU), working under the guidance of Virginia Espina, Ph.D.,
MT (ASCP), a Research Associate Professor at GMU’s Center for Applied Proteomics and
Molecular Medicine, contacted our Project Advisor, Dr. Erika Metzler Sawin. At the time, Ms.
Lawrence and Dr. Espina were applying for a 4VA Grant to support their research, and wanted to
work collaboratively across universities with two undergraduate nursing students from James
Madison University (JMU). Dr. Espina’s laboratory research focuses on how ductal carcinoma in
situ (DCIS) cells, which are pre-invasive, abnormal cells located within breast milk ducts, utilize
autophagy to survive in stressful environments. In addition, she is leading a clinical trial entitled
Preventing Invasive Breast Neoplasia with Chloroquine (PINC), aimed at evaluating the efficacy
and safety of administering chloroquine to patients with DCIS. Ms. Lawrence is leading an
epidemiological study to complement the work of Dr. Espina. Ms. Lawrence’s study focuses on
the use of chloroquine in female healthcare workers and the prevalence of DCIS in this
population.
As a part of their 4VA Grant proposal, Ms. Lawrence and Dr. Espina wanted their
undergraduate partners to complete a literature review focused on the use of chloroquine as an
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antineoplastic agent in various types of cancer. It was proposed that this literature review would
complement their research and be of potential use to them in their own studies. We were
extremely excited at this idea for an Honors Program Project, and developed our project proposal
collaboratively with our project advisor and readers at JMU, in addition to Ms. Lawrence and Dr.
Espina.
Unfortunately, the research team at GMU did not receive the 4VA Grant, and therefore
were unable to work as closely in collaboration with our efforts at JMU as both parties originally
intended. However, Ms. Lawrence and Dr. Espina encouraged us to continue our collaborative
work as undergraduate students and we chose to move forward with the originally approved
project topic under the primary guidance of Dr. Sawin. Although the collaborative, interuniversity aspect of this project became extremely limited following the rejection of the 4VA
Grant, we still have been in intermittent contact with Ms. Lawrence and Dr. Espina regarding the
progress of our project. We will submit the final project to them so that they may use it as a
complement to their own research, if they so choose.
In regards to how this literature review was authored collaboratively, we each
independently authored certain sections of the project. I wrote the preliminary sections titled
Autophagy and Chloroquine. Additionally, I focused on reviewing the literature regarding the
use of chloroquine in colon and lung cancers, including the limitations of these studies. In order
to ensure that there was consistent formatting and voice throughout the independently written
sections of the project, each student edited and reviewed the material written by the other
student. Finally, the sections titled Dedication, Preface, Acknowledgements, Nursing
implications, and Conclusion were authored collaboratively.
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Introduction
Chloroquine (CQ) is an oral lysosomotropic agent routinely used as an anti-malarial drug
(Espina & Liotta, 2013). In recent years, it has been discovered that CQ also possesses anticancer
effects, potentially due to the drug’s inhibition of autophagy (Kimura, Takabatake, Takahashi, &
Isaka, 2012). Autophagy is a normal cellular pathway that allows for the degradation of
cytoplasmic contents. In cancer cells autophagy can also serve as a pro-survival pathway under
stressful metabolic conditions, ultimately promoting the survival of malignant cells (Sui et al.,
2013). Therefore, in recent years CQ has been speculated as a potential antineoplastic therapy.
When administered in conjunction with typical chemotherapeutic agents, CQ also has the
potential to decrease acquired drug resistance, enhance the efficacy of chemotherapeutic agents,
and prevent pre-invasive cells from transitioning to invasive cells (Espina & Liotta, 2013).
However, this potential antineoplastic effect has been observed to vary somewhat between
cancer types and phases of tumorigenesis, and the precise antineoplastic mechanism of CQ is not
clearly understood (Sui et al., 2013).
The purpose of this literature review was to evaluate the current evidence in order to
compare the efficacy and safety of the use of CQ as an antineoplastic agent in various types of
cancer. Additionally, the conjectured antineoplastic effects of CQ discussed in each reviewed
study were compared in order to gain greater understanding of the probable mechanism of action
of CQ in cancer cells. Definitions for bolded terms can be found in Table 1.
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Methods
The literature review was completed using CINHAL, PubMed, Google Scholar and
Cochrane Library databases to locate articles published between 2010 and 2015 that discussed
the use of CQ as antineoplastic therapy in the treatment of various types and stages of cancer.
Search terms included chloroquine, neoadjuvant, antineoplastic, autophagy, and cancer. The
inclusion criteria for articles were, a) the article had to have been published in English between
2010 and 2015, b) publication in a peer-reviewed research journal, c) the article had to contain a
methods section, and d) the article had to report statistical evidence or a review of statistical
evidence from other studies. Any opinion pieces or articles not reporting original research were
excluded from the review.
Using the search terms, initial results were obtained from each database. Each article was
analyzed to determine if it met the inclusion criteria. Of the initial results from the databases,
seven articles met the inclusion criteria and are included in this review. These were then studied,
organized, and rated based on Fineout-Overholt, Melynck & Schultz’s hierarchy of evidence
(2005). The articles were then summarized and arranged into an evidence table (see Table 2 for
definitions of the levels of evidence and Table 3 for article summaries).
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Autophagy
Autophagy is a normal, “self protective cellular mechanism” that allows cells to degrade
cytoplasmic materials (Zou et al., 2013). During homeostasis, autophagy is used to rid cells of
damaged organelles and proteins. Under stressful conditions, such as starvation and hypoxia
caused by decreased blood supply, autophagy can be induced at higher rates in order to degrade
larger amounts of protein for cellular energy. This upregulation of autophagy allows cells to
survive even under stressful conditions (Kimura et al., 2012).
There are four steps in the process of autophagy, 1) initiation, 2) elongation, 3) fusion to
lysosomes, and 4) degradation. In the first step of initiation, a single membrane vessel is formed
in the endoplasmic reticulum. During elongation, this membrane expands to form an
autophagosome. The autophagosome engulfs the cytoplasmic materials to be degraded, and in
the third step fuses to lysosomes. In the fourth and final step, this fusion allows for the
degradation of engulfed cytoplasmic materials by lysosomal enzymes (Fukuda et al., 2015).
Autophagy-associated proteins regulate the process of autophagy and are used to measure
levels of autophagy in cells. The most commonly measured protein is LC3. In its cytoplasmic
form, this protein is referred to as LC3-I. During the second phase of autophagy, LC3-I is
converted from its cytoplasmic form to its autophagosome-associated form, known as LC3-II. By
measuring the levels of LC3-I and LC3-II in cells, autophagy rates can be determined by
comparing the quantity of LC3-I verse LC3-II. As levels of LC3-II increase in a cell, it indicates
that the rate of autophagy is also increasing (Zou et al., 2013).
The ability to measure autophagy rates is important in cancer research because it has been
observed that tumor cells utilize the process of autophagy to survive and flourish in nutrient
deprived environments. For this reason, greater amounts of research have focused on the
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potential use of autophagy inhibitors as antineoplastic therapy in recent years. One of the greatest
challenges to this research though is the dual role that autophagy can serve within cells (Sui et
al., 2013).
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Autophagy in cancer
Autophagy serves a dual purpose in cancer cells: promotion and suppression. In the role
of promoter, autophagy supports the survival of cancer cells. In contrast, as a suppressor,
autophagy causes cancer cell degradation. Precisely when and why autophagy serves this dual
role in cancer cells is poorly understood. Furthermore, it is believed autophagy’s role is affected
by a myriad of factors, including cell cycle, type of cancer, stage of tumorigenesis, metabolic
conditions, and the type of antineoplastic therapy being used to treat the malignancy (Kimura et
al., 2012).
In the promoter role, autophagy allows cells to produce energy in unfavorable
environments, including conditions of hypoxia, increased acidity, and nutrient deprivation. Such
environments are not compatible with healthy cells, but autophagy allows cancer cells to flourish
within these settings. Therefore, in these situations malignant cells are naturally selected over
normal, non-malignant cells that are unable to use autophagy to survive under these conditions
(Sui et al., 2013).
In the suppressor role, autophagy can induce autophagic cell death among cancer cells.
Autophagic cell death is a form of physiological cell death different from apoptosis, and it is
poorly understood why an increase in autophagy can sometimes lead to this cytotoxic effect.
However, it is clear that in these situations inhibiting autophagy prevents tumor cell suppression,
ultimately resulting in tumor cell growth (Sui et al., 2013).
In order to fully explore the potential use of medications known as autophagy inhibitors
and inducers as antineoplastic therapy, it is extremely important that researchers gain a better
understanding of when and why cancer cells utilize these dual roles of autophagy.
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Chloroquine
Chloroquine (CQ) is an autophagy inhibitor. Although routinely and effectively used as
an anti-malarial drug, this oral lysosomotropic agent has also been used to treat various other
conditions due to its anti-inflammatory effects, including rheumatoid arthritis, systemic lupus
erythematosus, and Sjögren’s syndrome (Fukuda et al., 2015). CQ has very few side effects
when administered at clinical doses, typically between 100 and 500 mg/day. In situations where
large doses of the drug are administered over extended periods of time, side effects can include
visual disturbances, gastrointestinal upset, electrocardiographic changes, headache, and pruritus
(Kimura et al., 2012).
CQ is currently being investigated in pre-clinical and clinical trials as a potential
antineoplastic therapy because of its inhibitory effects on autophagy and relatively low risk
profile. CQ interferes with autophagy in the third step of the process, fusion to lysosomes. By
raising the lysosomal pH, autophagosomes are unable to fuse with lysosomes, thus inhibiting
degradation of cytoplasmic material contained within autophagosomes (Espina & Liotta, 2013).
This disruption of autophagy directed cell survival is a key therapeutic method for using
chloroquine as an antineoplastic agent. Supplementation of chloroquine with traditional
chemotherapy may provide an innovative therapeutic regimen for those with various types of
cancer.
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Chloroquine as antineoplastic therapy in various cancer types: A review of the literature
Seven pre-clinical and clinical studies were analyzed for this literature review.
Summaries of the articles and subsequent findings can be found in Table 2. In total, one study
focused on brain cancer, two studies on breast cancer, two studies on colon cancer, one study on
endometrial cancer, and one study on lung cancer. Multiple facets of study design were
compared, including sample, type and stage of cancer studied, and outcome measures. The
findings are discussed in the following sections, followed by a comprehensive discussion of the
limitations, nursing implications, and conclusion of this literature review.
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Brain cancer
Rojas-Puentes et al. (2013) completed a randomized, double-blind, placebo controlled
clinical study examining the effect of CQ in combination with whole brain irradiation (WBI)
on brain metastases. The researchers stated that the results of several other studies suggest
combination and neoadjuvant CQ therapy can potentiate the effects of chemotherapy,
conventional surgery, and conventional therapy in primary brain tumors. Therefore, this study
aimed to determine if the same was true for CQ therapy in combination with WBI in patients
with brain metastases.
The study was completed at Instituto Nacional de Cancerología in Mexico City. In order
to participate in the study patients had to have greater than 3 brain metastases, and an
uncontrolled primary tumor. A total of 73 patients were included in the study, and all patients
were randomly divided into two separate arms; the CQ arm (39 patients) and the control arm (34
patients). Patients in the CQ arm received 30 Gray (Gy) of WBI in ten daily fractions along with
a daily dose of 150mg CQ one hour prior to radiation for all ten days, and once daily thereafter
for twenty-eight days (totaling four weeks of CQ treatment). Patients in the control arm also
received 30 Gy of WBI in ten daily fractions along with a daily placebo one hour prior to
radiation for all ten days and once daily thereafter for twenty-eight days. In addition to the WBI,
patients also received treatment for their primary tumor and non-brain metastases (Rojas-Puentes
et al., 2013).
Efficacy of treatments between arms of the study was measured in a number of ways. The
researchers compared overall response rate, toxicity, progression free survival of brain
metastases, overall survival, event free survival, and quality of life. Of these measures,
progression free survival of brain metastases was the only one that showed significant difference
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between study arms. One year after the treatment, the progression free survival of brain
metastases was 83.9% for the CQ arm, and 55.1% for the control arm. Even when multivariate
analysis was performed, CQ treatment was the only variable shown to be associated with better
progression free survival of brain metastases. There was no difference observed between arms in
regards to overall survival, overall response rate, or event free survival. No toxicity was observed
in either study arm, nor were any unique or increased side effects noted in the CQ arm (RojasPuentes et al., 2013).
The results of this study show that CQ can improve the progression free survival of brain
metastases when administered in combination with WBI. CQ causes this radiosensitization by
inhibiting autophagy, activating p53-mediated apoptosis, initiating oxidative stress, and
activating capase within tumor cells (Rojas-Puentes et al., 2013). When WBI was performed
following CQ treatment, the tumor cells targeted by the radiotherapy were less resistant due to
the fact that CQ had interfered with these numerous cellular functions that typically allow the
tumor to thrive and become more resistant in stressful environments. It is surprising that
improved progression free survival did not correlate positively with improved overall survival.
The researchers hypothesized that this relationship was not present in their results because many
of the patients in the study still died due to metastatic tumor progression outside of the brain.
Thus, even though the combination CQ therapy was successful at preventing further progression
of brain metastases, the patient’s primary tumors and other metastases were not as well
controlled with conventional treatment and may have contributed to the lack of significance in
survival. However, the results of this study are still important to review due to the fact that
progression free survival of brain metastases can help to improve patient quality of life (RojasPuentes et al., 2013).
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Breast cancer
DCIS is a non-invasive breast cancer that arises within the intraductal niche (Espina &
Liotta, 2011). DCIS is classified as a non-obligate precursor to invasive carcinoma, meaning that
DCIS may never progress to invasive, metastatic cancer. However, there is evidence to support
the idea that DCIS often serves as a precursor to malignant breast carcinomas (Espina,
Wysolmerski, Edmiston, & Liotta, 2013).
Prior to the pre-clinical trials completed by Espina and Liotta, the survival mechanisms of
DCIS were poorly understood (2011). The intraductal niche is a hypoxic, nutrient deprived
environment. In order to survive under these conditions, the cells must find an alternate way to
create energy than what is used during homeostasis (Espina et al., 2013). In order to determine
what alternative energy pathway is utilized by DCIS, Espina and Liotta studied DCIS cell
cultures and mouse xenograft models. The results of these pre-clinical trials demonstrated that
DCIS uses the process of autophagy in order to survive within the high-stress environment of the
intraductal niche. Additionally, it was theorized that in using this survival pathway DCIS cells
actually promote replication of the invasive, malignant phenotype. This supported the idea that
DCIS is most often a precursor to invasive breast carcinomas, and raised the question of whether
neoadjuvant therapy could be created to target these potential malignancy precursor cells (Espina
& Liotta, 2011).
In response to the results of these pre-clinical trials, Espina and Liotta are currently
conducting a clinical trial investigating the potential use of CQ as anti-autophagy therapy in
DCIS. This trial is entitled “Preventing Invasive Neoplasia with Chloroquine,” and is also
referred to as the PINC trial. The goal of the trial is to determine the efficacy and safety of CQ
when used as neoadjuvant therapy in the treatment of DCIS (Espina & Liotta, 2011).
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Neoadjuvant therapy indicates therapeutic strategies are being performed prior to primary
treatment for the neoplasm. In the PINC trial, participants are randomly assigned to receive a
dose of 250mg or 500mg of CQ on a weekly basis for one month prior to surgical removal of the
DCIS lesion. Prior to enrollment in the study and before surgical removal of the lesion, each
participant undergoes magnetic resonance imaging (MRI) to visualize the lesion and allow for
comparison of lesion size before and after CQ treatment. The removed lesion is then analyzed to
test for the presence of protein markers, including LC3-II, that indicate autophagy inhibition and
induction of apoptosis. Additionally, all removed lesions are genetically tested to determine if
there is any abnormal tissue present (Espina et al., 2013).
The PINC trial is currently accepting participants, therefore there are not currently any
published results from this study. Based on the results of the pre-clinical trials performed by
Espina and Liotta, it has been hypothesized that routine administration of CQ to DCIS patients
for four weeks prior to surgical removal of the lesion will result in decreased lesion size.
Additionally, it is predicted that lesions exposed to CQ will have decreased expression of protein
markers that indicate the presence of autophagy and apoptosis when compared to lesions not
exposed to CQ. Finally, it is anticipated that after treatment with CQ, DCIS lesions will not
contain genetically abnormal cells (Espina et al., 2013). The PINC trial is set to close in
September of 2016, and results should be available at some point after this date.
DCIS is not the only type of breast cancer in which the antineoplastic effects of CQ have
been investigated. In 2012, Maycotte et al. completed an in vitro study exploring the mechanism
through which CQ sensitizes primary breast tumor cells to chemotherapy. The goal of this study
was to gain greater understanding as to whether the antineoplastic effects of CQ are due to
autophagy inhibition.
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Two mouse breast cancer cell lines (67NR and 4T1) were cultured and grown in vitro.
The cells were then treated with 10μM of CQ and one chemotherapy agent; cisplatin, rapamycin,
or LY294002. Various outcomes were measured including autophagic flux, short and long term
survival assays, and induction of apoptosis. The results of this study showed that each of the
chemotherapy drugs used induced autophagy in the breast cancer cells. Additionally, when
treated with CQ the breast cancer cells became more sensitive to the chemotherapy drugs
(Maycotte et al., 2012).
Most notable were the results produced when the researchers blocked autophagy prior to
autophagosome formation. Typically, CQ inhibits autophagy at the third stage of the process,
when the autophagosome fuses to the lysosome. By blocking autophagy prior to this point in the
process, the researchers were able to observe if CQ exhibited sensitizing effects on the breast
cancer cells through a process other than autophagy inhibition. The results showed that CQ did
still sensitize the cells to chemotherapy treatment, indicating that the antineoplastic effects of CQ
are independent of autophagy in these mouse breast cancer cell lines. Furthermore, this implies
that mechanisms other than autophagy inhibition also need to be considered when discussing the
antineoplastic effects of CQ in human breast cancer cells (Maycotte et al., 2012).
Given these intriguing results, the researchers delved further into discovering if
autophagy played any role in the sensitization of mouse breast cancer cells to cisplatin,
rapamycin, and LY294002. Three extremely important results were observed. First, sensitization
to the chemotherapy drugs was observed in mouse breast cancer cells in which the genes that
regulate autophagy were silenced. Surprisingly, short and long term assays showed that CQ
sensitized the cells to the chemotherapy drugs despite the fact that autophagy was not occurring
in these gene-silenced cells. Secondly, it was observed that the chemosensitization effects
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elicited by CQ in mouse breast cancer cells without autophagy-associated proteins were similar
to those results seen in mouse breast cancer cells with autophagy-associated proteins. Thirdly,
short and long term assays showed that BafA, another autophagy inhibitor that prevents
autophagy at the same stage as CQ, was unable to produce sensitization to the chemotherapy
drugs in these mouse breast cancer cell lines. All together, these results further supported the
idea that CQ sensitization to cisplatin, rapamycin, and LY294002 in these mouse breast cancer
cells is independent of autophagy inhibition (Maycotte et al., 2012).
Given that these findings directly contradict what is widely believed to be the mechanism
behind the antineoplastic effects of CQ, it is hard to understand these results. Furthermore, it is
difficult to comprehend how researchers such as Espina and Liotta have produced contradictory
results in similar in vitro studies (2011). What is extremely important to remember when
evaluating these and other results is that the protective and non-protective effects of autophagy in
tumor cells are poorly understood and believed to vary greatly between cancer types, among
other factors. As conjectured by Maycotte et al. (2012), in order to better understand the potential
for antineoplastic therapy through use of CQ and other autophagy inhibitors, more selective
autophagy inhibitors may need to be developed. This would allow for more specific influence of
autophagy and improved comprehension of how this cellular process affects the proliferation or
death of cancer cells, and its interaction with other cellular processes, such as apoptosis
(Maycotte et al., 2012).

19

CHLOROQUINE AS ANTINEOPLASTIC THERAPY
Colon cancer
Despite the increased survival rates due to treatment of colon cancer with chemotherapy
and radiation, there are many incidences of colon cancer that remain significantly noncompliant
to antineoplastic treatment. Selvakumaran, Amaravadi, Vasilevskaya, and O'Dwyer (2013)
completed a study that investigated the effects of autophagy inhibition on colon cancer cells in
vitro and the effects of bevacizumab and oxaliplatin therapy in combination with CQ in vivo.
The goal of this study was to determine the role autophagy plays in the protection of colon
cancer cells from the effects of chemotherapy. Also, the study aimed to establish if CQ can
enhance the cytotoxicity of bevacizumab and oxaliplatin, chemotherapy drugs commonly used
to treat colon cancer.
In the in vitro study arm, eight colon cancer cell lines were cultured. Half of the colon
cancer cells were grown in normal growth medium, and half were grown in medium treated with
oxaliplatin. All colon cancer cells were grown under hypoxic conditions meant to stimulate the
hypoxic stress cancer cells experience when proliferating in nutrient poor environments. After
cells were allowed to proliferate, outcome measures included cytotoxicity and inhibition of
autophagy (Selvakumaran, 2013).
The results of the in vitro study arm showed that hypoxic conditions cause induction of
autophagy in colon cancer cells. Furthermore, autophagy induction rates were shown to increase
in cells grown in oxaliplatin treated media, indicating that cancer cells use autophagy to survive
under stressful conditions. This is important to understand because if autophagy allows colon
cancer cells to resist chemotherapy drugs, perhaps inhibiting autophagy would allow for
increased sensitivity to chemotherapy drugs (Selvakumaran, 2013).
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In the in vivo study arm, mice were inoculated with one of the colon cancer cell lines.
The cancer cells were allowed to proliferate until a tumor size of 400mm was reached, at which
point the mice were separated into eight study groups. Each group received a different treatment
combination; 1) control group, thus no treatment applied; 2) bevacizumab only; 3) oxaliplatin
only; 4) combination of bevacizumab and oxaliplatin; 5) chloroquine alone; 6) combination of
bevacizumab and chloroquine; 7) combination of oxaliplatin and chloroquine; 8) combination of
bevacizumab, oxaliplatin, and chloroquine. All dose quantities and frequencies were kept
constant among groups, and all concentrations used were clinically relevant, meaning that the
doses used in vitro are comparable to that which would be administered to patients clinically.
Outcome measures included tumor size and rates of autophagy inhibition (Selvakumaran, 2013).
The results of the in vivo study show that CQ potentiates the cytotoxic effects of
bevacizumab and oxaliplatin when used in combination with these chemotherapy drugs. When
tumor sizes were compared among treatment groups, mice that received combination therapy of
CQ with either or both bevacizumab and oxaliplatin showed the greatest reduction in tumor size.
Additionally, mice in these combination treatment groups showed the greatest rates of autophagy
inhibition, as indicated by lower levels of LC3-II within the tumor cells (Selvakumaran, 2013).
Overall, the results from the in vitro and in vivo study arms suggest that CQ causes
increased sensitivity of colon cancer cells to bevacizumab and oxaliplatin through the inhibition
of autophagy. While this certainly is part of the antineoplastic mechanism of CQ, Selvakumaran
et al. state that this study design did not allow for the distinction between autophagy inhibition
and other potential unknown cytotoxic effects of CQ. Therefore, further research needs to be
completed in order to investigate these other potential cytotoxic effects of CQ in colon cancer
(2013).
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The results of a study by Choi, Yoon, Won, Park, and Lee (2012) are an interesting
complement to the results found by Selvakumaran et al.(2013). Choi et al. investigated the anticancer effects of 5-fluorouracil (5-FU) and CQ combination therapy in colon cancer cells in an in
vitro study. The goal of this study was to determine the effects of autophagy inhibition on the
sensitivity of colon cancer cells to 5-FU, a typical chemotherapy agent used to treat colon cancer
(2012).
One colon cancer cell line was cultured and grown in vitro. Cells were allowed to
proliferate, and were then separated into six treatment groups. Four experimental groups were
treated with four varying doses of CQ, and two groups served as controls. One control group was
treated with just 5-FU, and one with just CQ. After the experimental groups were treated with
CQ, the cells were exposed to 5-FU. Outcome measures included growth inhibition, cell cycle
distribution, induction of apoptosis, and disruption of autophagy (Choi, 2012).
The results of the study showed that autophagy was induced at greater rates when colon
cancer cells were treated alone with 5-FU, indicating that this drug induces autophagy. However
autophagy rates were shown to decrease when treated with 5-FU and CQ combination therapy,
indicating that CQ inhibited autophagy among these cells despite treatment with 5-FU (Choi,
2012).
Similar to Selvakumaran et al. (2013), Choi et al. speculated whether there were
cytotoxic effects of CQ aside from autophagy inhibition causing increased sensitivity of colon
cancer cells to 5-FU that were not being measured by the study design. Therefore, Choi et al.
evaluated the cell cycle distribution among colon cancer cells treated with 5-FU and CQ. The
results showed that combination therapy with the two drugs caused an increase in colon cancer
cells arrested during the G1 cell cycle. Apoptosis occurs in the sub-G1 cell cycle; therefore CQ
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combination therapy was not causing an increase in apoptosis, but rather an increase in G1 cell
cycle arrest. Thus, it was deduced that the antineoplastic effects of CQ in colon cancer cells
might be due to the arrest of the G1 cell cycle (2012).
These results regarding the potential cytotoxic effects of CQ aside from autophagy
inhibition are interesting for two major reasons. Firstly, in the conclusion of their 2013 study,
Selvakumaran et al. stated that it could not be determined if CQ potentiated the cytotoxic effects
of bevacizumab and oxaliplatin solely through autophagy inhibition because their study design
did not allow for distinction between autophagy inhibition and other potential unknown cytotoxic
effects of CQ.
Secondly, Zou et al. performed a study focused on the antineoplastic effects of CQ in
lung cancer in which CQ’s inhibition of autophagy was found to induce increased rates of
apoptosis (2013). The results presented here by Choi et al. somewhat contradict these findings
due to the fact that Choi et al. state the rates of apoptosis were not found to be significantly
different between cells treated with 5-FU only and cells treated with combination 5-FU and CQ
(2012). However, it is important to remember that the antineoplastic mechanism of CQ is not
well understood and is believed to work differently in various cancer types. While it is
interesting to draw these comparisons between studies, it must be understood that this research is
currently evolving. Overall it can be concluded that in order to further investigate all of the
potential cytotoxic effects of CQ in colon cancer cells, more pre-clinical and clinical research is
necessary.
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Endometrial cancer
The role of autophagy in endometrial cancer has not been studied extensively; therefore it
is unclear how autophagy inhibitors, such as CQ, affect this cancer type. Fukuda et al. (2015)
investigated the effects of CQ in endometrial cancer cells in an in vitro study. The purpose of this
study was threefold; 1) to determine the antineoplastic effects of CQ in endometrial cancer, 2) to
determine if CQ causes autophagy inhibition in endometrial cancer cells, and 3) to determine if
combination therapy with CQ can cause increased sensitivity in cisplatin-resistant endometrial
cancer cells.
Six endometrioid adenocarcinoma cell lines were cultured and grown in vitro. After this
period, the cells were continuously exposed to varying doses of CQ for 14 hours. The CQ
concentrations used were clinically relevant at 0.2-100μM (Fukuda et al., 2015).
Various outcome measurements were used to analyze the results of this experiment,
including the number of colonies formed, cell cycle distribution, induction of apoptosis, and
disruption of autophagy. In general, it was observed that as the dose of CQ increased, the number
of colonies formed decreased. When analyzed in combination with the cell cycle distribution
results, it was determined that CQ inhibited growth of endometrial cancer cells through the
induction of apoptosis during the sub-G1 phase of the cell cycle, the phase that occurs directly
before proteins and mRNA are synthesized within the cell. Additionally, a decrease in LC3-II
was observed following the addition of CQ, and this decrease in LC3-II correlated inversely with
increased doses of CQ. Overall, these results show that CQ suppresses the growth of endometrial
cancer cells (Fukuda et al., 2015).
To better understand the mechanism through which CQ causes endometrial cancer cell
growth suppression, the researchers used gene silencing to create a collection of cells that did not
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contain the autophagy-associated proteins necessary to regulate the process of autophagy. When
these cells incapable of autophagy were then treated with CQ to measure its anti-proliferative
effects, a decrease in suppression was seen. This result indicates that CQ relies, at least in part,
on autophagy inhibition to suppress the growth of endometrial cancer cells (Fukuda et al., 2015).
In order to investigate the effects of CQ in endometrial cancer further, the researchers
created a line of resistant cells. These cells were cultured in a medium containing the
chemotherapy agent cisplatin for three months. After confirming resistance, LC3-II expression
was measured in the cisplatin resistant cells as compared to the non-cisplatin resistant cells. The
results showed that LC3-II expression was much greater in resistant cells, indicating that
resistant cells use the autophagy pathway under periods of stress to become and remain resistant
to cisplatin. Intrigued, the researchers then treated the resistant cells with CQ in varying doses.
The results showed that CQ and cisplatin combination therapy caused cisplatin resistant cells to
become re-sensitized to cisplatin. However in non-resistant cells, combination therapy with CQ
had no effect on the efficacy of cisplatin (Fukuda et al., 2015).
The results of this study provide a strong foundation regarding the effects of CQ in
endometrial cancer. Of greatest interest is the idea that the anti-proliferative effects of CQ are in
some amount dependent on autophagy inhibition. The researchers speculate that induction of
apoptosis may be a second contributing factor affecting the anti-proliferative effects of CQ. The
relationship between autophagy and apoptosis is extremely complex, and more research is
needed to determine exactly how these two processes interact (Fukuda et al., 2015).
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Lung cancer
In 2013, Zou et al. designed a study performed in vitro and in vivo to investigate why
some non-small cell lung cancer (NSCLC) tumors are innately resistant to epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors. It is understood that NSCLC tumors with
wild-type EGFR are innately resistant to EGFR tyrosine kinase inhibitors, while NSCLC tumors
with activating EGFR mutations are sensitive to this class of chemotherapeutic drug. Previously
the reasons for this innate resistance of NSCLC cells with wild type EGFR had not been
thoroughly examined, although it was speculated that autophagy played a role in the acquisition
and continuation of resistance to traditional chemotherapy. Thus, the aim of the study was to
properly assess the role of autophagy in EGFR tyrosine kinase inhibitor-mediated cytotoxicity
(Zou et al., 2013).
In the in vitro study arm, four NSCLC cell lines were cultured and treated with assorted
concentrations of erlotinib, an EGFR tyrosine kinase inhibitor currently approved for treatment
of NSCLC tumors, CQ, or combinations of the two drugs. Two of the NSCLC cell lines used had
wild type EGFR (erlotinib-resistant), and two had activating EGFR mutations (erlotinibsensitive). After the cells were allowed to proliferate for a week, various outcome measures were
assessed, including cell proliferation, cell cycle analysis, induction of apoptosis, and disruption
of autophagy (Zou et al., 2013).
The results of the in vitro study arm showed that combination therapy with erlotinib and
CQ caused the greatest enhancement of erlotinib cytotoxicity in both erlotinib-resistant and
sensitive NSCLC cells. Specifically, when treated with combination therapy of the two drugs a
70-93% reduction in colony size was seen in erlotinib-resistant cells and an 80-95% reduction
was seen in erlotinib-sensitive cells (Zou et al., 2013).
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Given these significant results, the researchers also investigated the mechanism through
which CQ caused enhanced cytotoxicity of erlotinib. In order to determine this mechanism,
autophagy induction levels and rates of apoptosis were compared among cells treated with
erlotinib only, CQ only, or a combination of erlotinib and CQ. The rates of autophagy in cells
treated with CQ alone compared to cells treated with erlotinib and CQ were surprisingly very
similar, indicating that CQ does not enhance the cytotoxicity of erlotinib through the inhibition
of autophagy. Additionally, it was observed that when both lines of NSCLC cells were treated
with a combination of the two drugs apoptosis was induced at higher rates than when cells were
treated with either drug alone (Zou et al., 2013).
These results indicate that CQ increases NSCLC cell sensitivity to erlotinib through the
enhancement of apoptotic pathways. In order to test this final hypothesis, the researchers
cultured a line of NSCLC cells in which the genes that regulate autophagy were silenced.
Through these methods, researchers were able to observe that apoptosis was also induced at
increased rates in gene-silenced cells. These results indicate that the inhibition of autophagy by
CQ allows for the induction of an “apoptotic cascade” by erlotinib, ultimately resulting in an
increased sensitivity of NSCLC cells to the chemotherapy drug (Zou et al., 2013).
In the in vivo study arm, mice were inoculated with two of the NSCLC cell lines. One of
the cell lines used had wild type EGFR (erlotinib-resistant), and one had activating EGFR
mutations (erlotinib-sensitive). After seven days, tumor size was evaluated and the mice were
divided into four groups. The first group served as the control, the second received only erlotinib,
the third received only CQ, and the fourth received combination therapy of erlotinib and CQ.
Medications were administered at regular intervals over the course of three weeks and all doses
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were considered clinically relevant. Outcome measures included mouse weight and tumor size
(Zou et al., 2013).
The results of the in vivo study arm support the previously discussed results of the in vitro
study; combination therapy of erlotinib and CQ causes a significantly greater increase in the
cytotoxic effects of erlotinib in erlotinib-resistant and sensitive cells than either drug can elicit
alone. The mechanism through which CQ causes enhanced cytotoxicity of erlotinib cannot be
attributed to the inhibition of autophagy alone, and may potentially be due to an increased
induction of apoptosis (Zou et al., 2013).
Overall, the results of this study are highly clinically relevant because the researchers
were able to elicit sensitivity to erlotinib among innately resistant NSCLC cells (Zou et al.,
2013). With further clinical research to help explain the safety of CQ combination therapy in
patients, combination therapy of erlotinib and CQ could prove a groundbreaking new treatment
option for patients with tumors that are resistant to traditional treatment options.
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Limitations
Overall, the greatest limitation of this literature review was the great variance between
the study designs of the reviewed articles. Each study had dissimilar samples, methods, and
outcome measurements, thus making drawing comparisons among them difficult. Also, the
literature regarding the use of chloroquine as antineoplastic therapy is still rather limited, as is
emphasized in the results of this review. Despite these overarching limitations, the reviewers
made every effort to ensure that all discussions were comprehensive and inclusive of each article
that met the inclusion criteria.
A full list of limitations of the seven articles included in the review can be seen in Table
3. Overall, common limitations included small sample size (Rojas-Puentes et al., 2013), results
produced only in vitro, thus limiting their potential application in vivo (Espina et al., 2013; Choi
et al., 2012; Fukuda et al., 2015; Zou et al., 2013), and the potential for unknown and therefore
immeasurable cytotoxic effects of CQ influencing its antineoplastic effects (Selvakumaran et al.,
2013; Maycotte et al., 2012).
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Nursing implications
As CQ is further investigated as a potential antineoplastic therapy, it is important for
nurses to remain abreast of its evolving use. CQ is currently being studied in pre-clinical and
clinical trials to determine its safety and efficacy when used alone and in combination with
traditional chemotherapy to treat various types and stages of cancer. According to 2012 United
States Cancer Statistics (USCS), the types of cancer analyzed in this review are among the top
ten most prevalent cancer types in the United States (U.S. Department of Health and Human
Services, Centers for Disease Control and Prevention, & National Cancer Institute, 2015).
Furthermore, cancer is the leading cause of morbidity and mortality both within the United States
and worldwide (World Health Organization, 2015). It is essential that nurses are educated on this
drug and current research about its use because as greater understanding is gained about the
antineoplastic mechanism of CQ and its safety in human use, it is possible that nurses will begin
to see more widespread use of the drug to treat these deadly cancers. Thus, nurses should remain
informed regarding the current research surrounding CQ so that they understand the benefits,
indications, contraindications, and side effects of this likely antineoplastic therapy.
Additionally, by remaining informed of the current research surrounding chloroquine
nurses will better understand how to organize care for patients receiving this therapy. In
particular, nurses should be aware of the important educational, assessment, and interventional
needs for patients receiving chloroquine. Education is essential prior to beginning this treatment
due to the fact that it is extremely new and experimental. Nurses must be able to disseminate the
research in a manner that can be understood by patients and families who are not familiar with
the medication. Also, nurses must be mindful of the benefits and risks associated with
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chloroquine treatment for each individual patient in order to allow for a fully informed consent
for treatment.
When assessing patients receiving chloroquine as antineoplastic therapy, nurses must be
aware of common side effects in order to assess for the presence of complications. While some
side effects are benign, such as gastrointestinal upset, rash, and headache, others can have longterm negative effects, including ophthalmic degradation (Espina & Liotta, 2013). Nurses must
understand what to look for during an assessment in order to intervene properly to promote
patient comfort and prevent long-term negative effects. Ultimately, informed nurses will be best
able to adequately educate, care, and advocate for patients receiving chloroquine as
antineoplastic therapy.
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Conclusion
The potential use of CQ as antineoplastic therapy in various cancer types and at different
stages of tumorigenesis is an extremely exciting discovery. The drug has been found to 1)
increase sensitization of breast, colon, endometrial, and lung cancers to traditional chemotherapy
(Maycotte et al., 2012; Selvakumaran et al., 2013; Choi et al., 2012; Fukuda et al., 2015; Zou et
al., 2013); 2) reduce proliferation of pre-invasive breast neoplasms (Espina et al., 2013); and 3)
hinder the progression of brain metastases (Rojas-Puentes et al., 2013). Given these results, it is
believed that CQ could be used as combination therapy to improve the anti-proliferative effects
of traditional chemotherapy (Maycotte et al., 2012; Selvakumaran et al., 2013; Choi et al., 2012;
Fukuda et al., 2015; Zou et al., 2013; Rojas-Puentes et al., 2013). Additionally, CQ is
hypothesized to prevent the progression of pre-invasive neoplasms to invasive carcinomas, and
to decrease the presence of genetically abnormal precursor cells (Espina et al., 2013).
The greatest question still surrounding CQ’s use as antineoplastic therapy is the exact
mechanism through which it elicits these cellular responses. Some results support the idea that
the antineoplastic effects of CQ are primarily due to its inhibition of autophagy (Espina et al.,
2013; Zou et al., 2013; Choi et al., 2012); while others show that the drug’s antineoplastic effects
are only either partially due to (Selvakumaran et al., 2013; Fukuda et al., 2015) or completely
independent of autophagy inhibition (Maycotte et al., 2012). In order to gain better
understanding of the antineoplastic effects of CQ, further research must focus on the protective
and non-protective cellular functions of autophagy and how this cellular process interacts with
apoptosis (Maycotte et al., 2012).
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Table 1: Glossary of scientific terms
Term
Antineoplastic

Definition
Inhibition of tumor development
Normal process of cell death which plays an important role in healthy
Apoptosis
body development
Autophagosome
A vesicle which fuses with lysosomes during autophagy
Capase
Protease enzymes that are essential in programmed cell death
Treatment of a tumor with medicine to make it more sensitive to
Chemosensitization
radiation
Cytotoxicity
Toxic to living cells
Hypoxia
Diminished amount of oxygen
“In glass,” Study performed with microorganisms outside of their
In vitro
natural biological environment
“Within the living,” Studies performed on whole, living organisms,
In vivo
including humans or animals
Lysosomotropic agent Type of drug which accumulates in the lysosomes of the cells
Administration of therapeutic agents before the onset of a main
Neoadjuvant
treatment
Radiosensitization
Act of sensitizing tumor cells to radiation therapy
Tumorigenesis
Process of tumor formation
Type of drug which inhibits tyrosine kinases, enzymes responsible
Tyrosine kinase inhibitor
for the activation of various proteins
Whole brain irradiation
Type of treatment for patients with whole brain metastases
(WBI)
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Table 2: Levels of evidence*
Level of
evidence
1
2
3
4
5
6
7

Definition
Systematic review or meta-analysis of all relevant randomized controlled trials
(RCTs); Evidence-based clinical practice guidelines based on systematic
reviews of RCTs
At least one well-designed RCT
Well-designed controlled trials without randomization
Well-designed case-control and cohort studies
Systematic reviews of descriptive and qualitative studies
Single descriptive or qualitative study
Expert opinion

* Fineout-Overholt et al., 2005
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Table 3: Summarized evidence table
Author,
Year, Level
of Evidence
(LOE)
RojasPuentes, L.,
GonzalezPinedo, M.,
Crismatt, A.,
OrtegaGomez, A.,
GamboaVignolle, C.,
NuñezGomez, R.,
DorantesGallareta, Y.,
et al., 2013

Type of
cancer,
Tumor stage
& Type of
study

Sample

Intervention

Outcomes
Assessed

Results

Limitations

• Brain
• Metastases
• In vivo

N=73 patients
between 18-80
years old

Two study
arms; one
arm (39
patients)
received
chloroquine
in addition to
whole brain
radiation, and
the other arm
(34 patients)
received a
placebo and
whole brain
irradiation

• Overall
response rate
• Toxicity
• Progression
free survival of
brain
metastases
• Overall survival
• Event free
survival
• Quality of life

The use of
chloroquine with
whole brain
irradiation for
treatment of brain
metastases increases
the chance of the
patient’s progression
free survival

Small sample size,
No outcome
measure used to
assess the reason for
CQ’s antineoplastic
effect

• Breast
• Pre-invasive
lesions
• In vitro & In
vivo

In vitro: DCIS
cells harvested
and grown in
vitro

In vitro:
In vitro:
Cultured cells • Autophagy
treated with
levels
chloroquine
• Induction of
alone
apoptosis
• Disruption of
In vivo:
autophagy
Patients
randomly
In vivo:
assigned to
• Reduction in
receive
DCIS lesion
250mg or
volume
500mg of CQ
• Pathologic
once a week
regression
for one month
• Reduction or
prior to
elimination of
surgical
genetically
removal of
abnormal
DCIS lesion
tumorigenic
DCIS stem-like
cells
• Suppression of
cellular
proliferation
• Induction of
apoptosis
• Disruption of
autophagy

In vitro: CQ therapy
alone caused DCIS
cell death in less
than one week of
treatment

In vitro: The cells
tested cannot be
formally classified
as “cancer stem
cells,” thus limiting
the potential
application of these
results in vivo

LOE: 2
Espina, V.,
Wysolmerski,
J., Edmiston,
K., Liotta, L.
A., 2013
LOE: 2

In vivo:
Currently
recruiting
clinical trial;
Participants must
be diagnosed
with either ERor ER+ DCIS
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Maycotte, P.,
Aryal, S.,
Cummings,
C. T.,
Thorburn, J.,
Morgan, M.
J., Thorburn,
A., 2012

• Breast
• Primary
tumor cells
• In vitro

Two mouse
breast cancer
cell lines (67NR
and 4T1)
cultured and
grown in vitro

Cells treated
• Autophagic
with one
flux
chemotherapy • Short and long
drug (either
term survival
cisplatin,
assays
rapamycin, or • Induction of
LY294002)
apoptosis
and CQ

CQ sensitizes breast
cancer cells to the
chemotherapy drugs
cisplatin, rapamycin,
and LY294002
through a method
other than
autophagy inhibition

Using the selected
outcome
assessments, it was
unable to be
determined through
which mechanism
other than
autophagy inhibition
CQ was able to
cause sensitization
to chemotherapy

• Colon
• Primary
tumor cells
• In vitro

A single colon
cancer cell line
was cultured and
grown in vitro

Cells were
treated first
with 5fluorouracil,
then with one
of four
varying doses
of CQ

• Growth
inhibition
• Cell cycle
distribution
• Induction of
apoptosis
• Disruption of
autophagy

Combination
therapy with CQ
caused sensitization
of colon cancer cells
to 5-fluorouracil

Only one colon
cancer cell line was
studied,
Results were
evaluated in vitro
only, thus limiting
the potential
application of these
results in vivo

• Colon
• Primary
tumor cells
• In vitro & In
vivo

In vitro: Eight
colon cancer cell
lines were
cultured and
grown in vitro

In vitro: Two
study arms;
one arm
served as the
control, and
the other arm
was exposed
to oxaliplatin
and CQ

In vitro:
• Cytotoxicity
• Disruption of
autophagy

In vitro:
Combination
therapy with CQ
increased sensitivity
to oxaliplatin in all
of the cell lines
tested

Outcome
assessments used in
vitro and in vivo
cannot distinguish
between
antineoplastic
effects caused by
autophagy inhibition
vs. potentially
unknown cytotoxic
effects of CQ

LOE: 3

Choi, J.,
Yoon, J. S.,
Won, Y.,
Park, B., Lee,
Y., 2012
LOE: 3

Selvakumaran
, M.,
Amaravadi,
R. K.,
Vasilevskaya,
I. A., &
O'Dwyer, P.
J., 2013
LOE: 3

In vivo: Mice
were inoculated
with one of the
colon cancer cell
lines

In vivo: Eight
study arms
received
various single
and
combination
therapy
treatments.
Medications
used included
CQ,
bevacizumab,
and
oxaliplatin
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• Tumor size
• Disruption of
autophagy

In vivo:
Combination
therapy with CQ
caused significantly
increased tumor
growth delay
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Fukuda, T.,
Oda, K.,
WadaHiraike, O.,
Sone, K.,
Inaba, K.,
Ikeda, Y.,
Miyasaka, A.,
et al., 2015

• Endometrial
• Primary
tumor cells
• In vitro

Six endometrioid
adenocarcinoma
cell lines were
cultured and
grown in vitro

Cells treated
with cisplatin
only until
resistance
was
established,
then treated
with
clinically
relevant doses
of CQ (0.2100 μM) for
fourteen days

• Lung
• Primary
tumor cells
• In vitro & In
vivo

In vitro: Four
wild-type EGFR
non-small cell
lung cancer cells
were cultured
and grown in
vitro

In vitro: Cells In vitro:
treated with
• Cell
erlotinib
proliferation
alone or
• Cell cycle
erlotinib and
analysis
CQ
• Induction of
apoptosis
In vivo: Two
• Disruption of
study arms;
autophagy
one arm was
treated daily
In vivo:
with 150mg
• Mouse weight
of erlotinib
• Tumor size
alone, and the
other arm was
treated daily
with 800mg
total of
erlotinib and
CQ

LOE: 3

Zou, Y., Ling,
Y., Sironi, J.,
Schwartz, E.,
Perez-Soler,
R., Piperdi,
B., 2013
LOE: 3

In vivo: Mice
were inoculated
with the wildtype EGFR nonsmall cell lung
cancer cells
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• Number of
colonies formed
relative to
control
• Cell cycle
distribution
• Induction of
apoptosis
• Disruption of
autophagy

Treatment of
cisplatin resistant
endometrial cancer
cells with CQ
partially restored
sensitivity to
cisplatin, at least
partly due to
autophagy inhibition

Measurement of
autophagy inhibition
done entirely in
vitro, unclear how to
measure effectively
in vivo, thus limiting
the ability to
replicate these
methods in vivo

In vitro: CQ can
partially overcome
resistance to
erlotinib in wildtype EGFR nonsmall cell lung
cancer cells through
inhibiting autophagy
and inducing
increased rates of
apoptosis

Results in both in
vitro and in vivo
studies limited to
very specific lung
cancer cell line,
cannot be
determined if these
results would hold
true in other lung
cancer cell types

In vivo: Tumor
growth was reduced
significantly in mice
treated with
combination
erlotinib and CQ
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